GO:0005542 folic acid binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005542 (folic acid binding) is a molecular function defined as binding to folic acid (pteroylglutamic acid), a vitamin B complex member essential for purine and pyrimidine synthesis.
• Folate binding proteins (FOLR1, FOLR2) and folate transporters (SLC19A1, SLC46A1) mediate cellular uptake and distribution of folates and antifolates such as methotrexate [1,3].
• Folic acid binding is not limited to dedicated transporters; serum proteins like alpha- and beta-casein and synthetic nanocarriers (PAMAM, chitosan) can bind folate, affecting drug delivery and assay design [2,4,5,6].
• Competitive ligand binding assays for vitamin B12 and folic acid rely on the specific interaction between folate and folate-binding protein, forming the basis of clinical radioassays.
• Folic acid-binding proteins can inhibit cellular folate uptake, a regulatory mechanism with implications for folate homeostasis and chemotherapy resistance.
• CRISPR-based knockout, knock-in, and overexpression models of folate-binding genes enable causal dissection of folate transport in cancer, neural tube defects, and inflammatory diseases [1,3].
Description
Folic acid binding (GO:0005542) is a molecular function that describes the selective interaction of a protein or molecule with folic acid (pteroylglutamic acid), a water-soluble vitamin B9 essential for one-carbon metabolism and nucleotide biosynthesis. This binding event is the first step in folate recognition, transport, and cellular uptake, and it is critical for maintaining intracellular folate pools required for DNA synthesis, repair, and methylation [1,3]. The QuickGO definition emphasizes that folic acid is widely distributed as a member of the vitamin B complex and is essential for the synthesis of purines and pyrimidines, underscoring the functional importance of this binding activity in cell proliferation and survival. Researchers study folic acid binding to understand nutrient transport, drug delivery, and the mechanisms of antifolate chemotherapeutics such as methotrexate [1,3]. The interaction between folate and folate-binding protein (FBP) has been exploited for decades in clinical radioassays for vitamin B12 and folic acid, demonstrating the high specificity and affinity of this molecular function. Moreover, folic acid binding is not restricted to canonical folate receptors; serum proteins like alpha- and beta-casein and synthetic nanoparticles can also bind folate, which has implications for bioavailability and targeted drug delivery [2,4,5,6]. Understanding the structural and mechanistic basis of folic acid binding is therefore relevant to nutrition, pharmacology, and cancer biology [1,3,7].
folic acid binding At A Glance
| GO ID | GO:0005542 |
|---|---|
| GO term | folic acid binding |
| Ontology | molecular_function |
| Synonym | folate binding; vitamin B9 binding; vitamin M binding |
| Major function | Binding to folic acid (pteroylglutamic acid), enabling folate recognition, transport, and cellular uptake for nucleotide synthesis |
| Definition source | QuickGO: Binding to folic acid, pteroylglutamic acid. Folic acid is widely distributed as a member of the vitamin B complex and is essential for the synthesis of purine and pyrimidines. |
| Related ligands | Folic acid, methotrexate, leucovorin, folate-PAMAM conjugates, folate-chitosan conjugates |
| Representative proteins | FOLR1, FOLR2, SLC19A1, SLC46A1, and serum proteins such as caseins |
What Is GO:0005542?
In our own words, GO:0005542 (folic acid binding) is the molecular function of selectively and non-covalently interacting with folic acid (pteroylglutamic acid), also known as vitamin B9 or vitamin M. This binding activity is essential for the recognition, transport, and cellular uptake of folate, a cofactor required for purine and pyrimidine synthesis and for one-carbon transfer reactions. The term encompasses binding by dedicated folate receptors and transporters as well as by other proteins and synthetic molecules that exhibit specific affinity for folic acid [1,3,6].
Why Is folic acid binding Important in Cell Biology?
Folic acid binding is fundamentally important because it governs the bioavailability and cellular uptake of folate, a vitamin essential for DNA synthesis, repair, and methylation. Disruption of folate binding and transport leads to folate deficiency, which is associated with megaloblastic anemia, neural tube defects, and increased cancer risk [1,7]. In pharmacology, the folate-binding protein is a target for antifolate drugs like methotrexate, and its binding properties determine drug efficacy and toxicity [1,3]. Additionally, folic acid binding is exploited in targeted drug delivery systems using folate-conjugated nanoparticles, which rely on specific binding to folate receptors overexpressed on cancer cells [2,4,5]. The clinical radioassay for vitamin B12 and folic acid, based on competitive ligand binding, remains a cornerstone of diagnostic testing, highlighting the practical importance of this molecular function.
• Essential for cellular uptake of folate, a cofactor for purine and pyrimidine synthesis.
• Mediates the mechanism of action of antifolate drugs such as methotrexate and leucovorin [1,3].
• Underlies targeted cancer therapy via folate-conjugated nanocarriers that bind folate receptors [2,4,5].
• Folate-binding protein can inhibit cellular folate uptake, serving as a regulatory mechanism.
• Competitive ligand binding assays for vitamin B12 and folic acid depend on specific folate-protein interactions.
• Folate deficiency due to impaired binding is linked to neural tube defects and megaloblastic anemia.
• Folic acid binding by serum proteins like caseins affects folate bioavailability from milk.
• Nanoparticle-folate conjugates are used to study DNA and tRNA binding efficacy, linking folate binding to nucleic acid delivery [2,4,5].
• Folate receptor overexpression in cancer makes folic acid binding a biomarker and therapeutic target [1,3].
• CRISPR models of folate-binding genes enable causal studies of folate transport in development and disease [1,3].
Molecular Mechanism of folic acid binding
Ligand recognition and binding site architecture
In simple terms: Folic acid fits into a specific pocket on the protein, like a key in a lock.
Folic acid binding involves non-covalent interactions between the pteroylglutamic acid moiety and specific amino acid residues in the binding pocket of folate-binding proteins. The binding is highly specific, as demonstrated by the interaction of folic acid with folate binding protein, where conjugation chemistry influences the binding affinity. Structural studies using spectroscopic and computational methods have located the binding sites of folic acid on milk alpha- and beta-caseins, revealing that folate interacts with hydrophobic and electrostatic regions. The specificity of this binding is exploited in competitive ligand binding radioassays for vitamin B12 and folic acid, where the folate-binding protein selectively recognizes folate over other vitamins.
Cellular uptake and transport
In simple terms: Once folate binds to its receptor, the cell engulfs it to bring the vitamin inside.
Folic acid binding to membrane-associated folate receptors (e.g., FOLR1) and transporters (e.g., SLC19A1, SLC46A1) initiates cellular uptake through receptor-mediated endocytosis or carrier-mediated transport. The binding event is the first step in a cascade that delivers folate to the cytoplasm, where it is converted to tetrahydrofolate for one-carbon metabolism. Studies have shown that folic acid-binding protein can inhibit cellular uptake of folate, suggesting a regulatory role in transport. The interaction of folic acid with synthetic nanocarriers such as PAMAM and chitosan also facilitates cellular delivery of nucleic acids, indicating that binding can be engineered for therapeutic purposes [2,4,5].
Interaction with antifolates and therapeutic implications
In simple terms: Drugs like methotrexate mimic folate and compete for the same binding site.
Folic acid binding proteins also bind antifolate drugs such as methotrexate and leucovorin, which are structural analogs of folate. This cross-reactivity is the basis for methotrexate's mechanism of action, as it inhibits dihydrofolate reductase after being transported into cells via folate transporters. The conjugation-dependent interaction of folic acid with folate binding protein has been studied to optimize drug delivery and reduce toxicity. Understanding these interactions is critical for predicting drug resistance and designing better antifolate therapies [1,3].
Folate binding in serum and milk proteins
In simple terms: Some proteins in blood and milk can also grab folate, affecting how much is available to the body.
Beyond dedicated receptors, serum and milk proteins such as alpha- and beta-casein exhibit folic acid binding activity. The binding sites on caseins have been mapped, showing that folate interacts with specific regions that may influence its bioavailability from dairy products. This non-canonical binding expands the scope of GO:0005542 beyond transport to include nutrient sequestration and delivery. Such interactions are relevant for food science and for understanding folate status in different populations.
Nanoparticle and synthetic folate conjugates
In simple terms: Scientists attach folate to tiny particles to deliver drugs or DNA into cells.
Folic acid can be conjugated to synthetic nanoparticles such as PAMAM dendrimers and chitosan, which then exhibit folate binding activity that mediates interaction with DNA and tRNA [2,4,5]. These conjugates exploit the high affinity of folate for its receptor to achieve targeted delivery [2,4,5]. Studies have measured the binding efficacy of DNA and tRNA with folic acid-PAMAM nanoparticles, demonstrating that folate conjugation enhances nucleic acid delivery [2,4]. Similarly, folic acid-chitosan nanoconjugates bind DNA, highlighting the versatility of folate as a targeting ligand. These applications rely on the same molecular function defined by GO:0005542 [2,4,5].
Key Genes Involved in GO:0005542 folic acid binding
The following genes and proteins are directly involved in folic acid binding or are established models for studying this molecular function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FOLR1 | High-affinity folate receptor alpha; mediates cellular uptake of folic acid and antifolates | Target for cancer therapy and drug delivery; knockout models study folate transport [1,3] |
| FOLR2 | Folate receptor beta; expressed in placenta and hematopoietic cells | Role in folate transport during development and immune function |
| SLC19A1 | Reduced folate carrier; transports folates and methotrexate | Major route of antifolate drug uptake; polymorphisms affect drug response |
| SLC46A1 | Proton-coupled folate transporter; intestinal folate absorption | Mutations cause hereditary folate malabsorption |
| FOLH1 | Glutamate carboxypeptidase II; also known as prostate-specific membrane antigen | Folate hydrolase activity; target for prostate cancer imaging and therapy |
| GCPII | Glutamate carboxypeptidase II; hydrolyzes folate polyglutamates | Regulates folate bioavailability; studied in neurological disorders |
| MTHFR | Methylenetetrahydrofolate reductase; uses folate derivatives | Polymorphisms linked to folate metabolism and disease risk |
| MTR | Methionine synthase; uses methyltetrahydrofolate | Connects folate cycle to methylation reactions |
| DHFR | Dihydrofolate reductase; reduces folate to tetrahydrofolate | Target of methotrexate; key enzyme in folate cycle |
| GART | Phosphoribosylglycinamide formyltransferase; uses folate cofactors | Purine synthesis; folate-dependent enzyme |
| ATIC | AICAR transformylase; uses folate cofactors | Purine synthesis; folate-dependent enzyme |
| TYMS | Thymidylate synthase; uses methylenetetrahydrofolate | Pyrimidine synthesis; target of 5-fluorouracil |
| SHMT1 | Serine hydroxymethyltransferase; generates methylenetetrahydrofolate | One-carbon metabolism; folate-dependent |
| SHMT2 | Mitochondrial serine hydroxymethyltransferase | One-carbon metabolism in mitochondria |
| MTHFD1 | Methylenetetrahydrofolate dehydrogenase | Folate metabolism; links to nucleotide synthesis |
| MTHFD2 | Mitochondrial methylenetetrahydrofolate dehydrogenase | Folate metabolism in cancer cells |
| ALDH1L1 | 10-formyltetrahydrofolate dehydrogenase | Regulates folate pools; tumor suppressor candidate |
| CASP | Casein proteins (alpha, beta) in milk | Bind folic acid; affect folate bioavailability |
How Is folic acid binding Regulated?
Folic acid binding is regulated at multiple levels. The expression of folate receptors and transporters is modulated by folate status, with folate deficiency often upregulating receptor expression to enhance uptake. The binding affinity of folate-binding protein can be influenced by conjugation chemistry and post-translational modifications. Additionally, the interaction of folate with serum proteins like caseins may be affected by pH and ionic strength, which can alter folate bioavailability. Competitive binding with antifolates such as methotrexate can also regulate the effective availability of folate for cellular processes. At the cellular level, folate-binding protein can inhibit folate uptake, providing a feedback mechanism to prevent excessive folate accumulation.
folic acid binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FOLR1 | Ovarian cancer, drug delivery | Knockout and overexpression in cancer cell lines; folate-conjugated nanoparticle uptake assays [1,3] |
| SLC46A1 | Hereditary folate malabsorption | Knockout mice or patient-derived cells; folate transport assays |
| MTHFR | Neural tube defects, cardiovascular disease | Point mutation knock-in models for common polymorphisms |
| DHFR | Methotrexate resistance in cancer | Knockout and point mutation models to study drug binding |
| CASP (caseins) | Folate bioavailability from milk | In vitro binding assays with purified caseins |
Folic acid binding in cancer and antifolate therapy
Folate receptors are overexpressed in several cancers, including ovarian, lung, and breast cancers, making folic acid binding a target for tumor-selective drug delivery. The antifolate drug methotrexate relies on folate transporters to enter cells, and alterations in folic acid binding can lead to drug resistance [1,3]. Folate-conjugated nanoparticles exploit this binding to deliver chemotherapeutics specifically to cancer cells, reducing systemic toxicity [2,4,5]. Thus, understanding folic acid binding is critical for optimizing cancer therapy and overcoming resistance [1,3].
Folic acid binding and neural tube defects
Folate deficiency during pregnancy is a well-established risk factor for neural tube defects, and proper folic acid binding and transport are essential for fetal development. Mutations in folate transporters such as SLC46A1 can cause hereditary folate malabsorption, leading to severe developmental abnormalities. The binding of folate to its receptor is the first step in ensuring adequate folate supply to the developing embryo. Research into folic acid binding mechanisms informs public health recommendations for folic acid supplementation.
Folic acid binding in nutritional and metabolic disorders
Impaired folic acid binding can lead to megaloblastic anemia due to defective DNA synthesis. The interaction of folate with milk proteins like caseins affects folate bioavailability from dairy, which is relevant for nutritional planning. Competitive ligand binding assays for vitamin B12 and folic acid are used clinically to diagnose deficiencies, highlighting the diagnostic importance of this binding activity. Furthermore, folate-binding protein can inhibit cellular folate uptake, and dysregulation of this process may contribute to metabolic imbalances.
From folic acid binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FOLR1 mediate folate uptake in cancer cells? | FOLR1 knockout cell lines generated by CRISPR [1,3] |
| What is the effect of a specific point mutation in SLC46A1 on folate transport? | Point mutation knock-in cell lines |
| Can folate-conjugated nanoparticles deliver DNA efficiently? | Overexpression of folate receptors in target cells; nanoparticle binding assays [2,4,5] |
| How does folate binding to caseins affect bioavailability? | In vitro binding assays with purified caseins and folate |
| What is the role of folate-binding protein in inhibiting folate uptake? | Knockout of folate-binding protein in cell lines; uptake assays |
| Can we develop a competitive binding assay for folate diagnostics? | Recombinant folate-binding protein and radioassay development |
How to Study the folic acid binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Competitive ligand binding radioassay | Concentration of folate or vitamin B12 in samples | Clinical diagnosis of vitamin deficiencies |
| Fluorescence spectroscopy | Binding affinity and site location | Characterizing folate-protein interactions |
| Molecular docking | Predicted binding pose and energy | Modeling folate binding to caseins and receptors |
| Gel electrophoresis | DNA/tRNA binding efficacy of folate conjugates | Developing nanoparticle-based gene delivery [2,4,5] |
| CRISPR knockout | Loss-of-function phenotype | Studying folate transport genes [1,3] |
| CRISPR knock-in | Effect of specific mutations | Modeling human polymorphisms in folate transporters |
| Overexpression | Gain-of-function effects | Enhancing folate receptor density for drug delivery [1,3] |
| Folate uptake assay | Cellular internalization of folate | Measuring transport activity in knockout/knock-in cells [1,7] |
Competitive ligand binding assays
Competitive ligand binding assays are classic methods for measuring folic acid binding. These assays use the specific interaction between folate and folate-binding protein to quantify folate levels in clinical samples, as demonstrated for vitamin B12 and folic acid radioassays. The principle involves competition between labeled and unlabeled folate for a limited number of binding sites on the folate-binding protein. This method is highly sensitive and remains a standard in clinical diagnostics.
Spectroscopic and computational binding studies
Spectroscopic techniques such as fluorescence quenching and circular dichroism, combined with molecular docking, are used to locate binding sites and determine binding constants for folic acid with proteins like caseins. These methods reveal the thermodynamic and structural basis of folic acid binding, including the involvement of hydrophobic and electrostatic interactions. Computational modeling helps predict how modifications to folate or the protein affect binding affinity.
Nanoparticle conjugation and nucleic acid binding assays
Folic acid can be conjugated to nanoparticles such as PAMAM and chitosan, and the resulting conjugates are tested for their ability to bind DNA and tRNA [2,4,5]. These assays measure binding efficacy using gel electrophoresis, fluorescence spectroscopy, or dynamic light scattering [2,4,5]. Such methods are used to develop targeted gene delivery systems that exploit folic acid binding for cellular uptake [2,4,5].
CRISPR-based functional genomics
CRISPR knockout, knock-in, and overexpression models enable causal studies of genes involved in folic acid binding [1,3]. For example, knocking out FOLR1 in cancer cells can reveal its role in folate uptake and drug sensitivity [1,3]. Point mutations can be introduced to mimic human polymorphisms in transporters like SLC46A1. These models are combined with binding assays and phenotypic readouts to dissect the molecular function of folic acid binding [1,3].
How CRISPR Can Be Used to Study GO:0005542 folic acid binding
Knockout
CRISPR knockout of genes encoding folate receptors (e.g., FOLR1) or transporters (e.g., SLC19A1) eliminates folic acid binding and uptake, allowing researchers to study the consequences for cell proliferation, drug sensitivity, and folate homeostasis [1,3]. Knockout models are essential for validating the specific contribution of each gene to folate transport.
Point Mutation
Point mutations can be introduced into folate-binding proteins to mimic naturally occurring polymorphisms or to dissect the contribution of specific amino acid residues to ligand binding. For example, mutations in SLC46A1 identified in hereditary folate malabsorption can be modeled to understand transport defects. Such models provide insights into structure-function relationships.
Knock-in
Knock-in of tagged or reporter versions of folate-binding proteins allows real-time tracking of protein localization and binding dynamics. Knock-in of human disease-associated variants into model organisms or cell lines enables studies of folate transport in a physiological context. This approach is valuable for understanding how mutations affect folic acid binding in vivo.
Overexpression
Overexpression of folate receptors or transporters increases folic acid binding capacity and can enhance cellular uptake of folate-conjugated drugs or nanoparticles [1,3]. Overexpression models are used to study the effects of elevated folate transport on cell growth and to test targeted delivery systems [1,3]. They also help identify saturation effects and regulatory feedback.
How EDITGENE Supports folic acid binding Research
Researchers studying folic acid binding-related genes often need to determine whether a candidate gene is causally involved in folate transport, drug response, or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes associated with GO:0005542.
Contact EDITGENE today to design your custom CRISPR model for folic acid binding research.
Frequently Asked Questions About folic acid binding
What is folic acid binding?
Folic acid binding (GO:0005542) is the molecular function of selectively interacting with folic acid (vitamin B9), a vitamin essential for nucleotide synthesis and one-carbon metabolism.
What genes are involved in folic acid binding?
Key genes include FOLR1, FOLR2, SLC19A1, SLC46A1, and FOLH1, which encode receptors and transporters that bind and internalize folate.
How is folic acid binding measured?
It is measured using competitive ligand binding assays, fluorescence spectroscopy, and cellular uptake assays, often with radiolabeled folate [8,6].
Why is folic acid binding important in cancer?
Folate receptors are overexpressed in many cancers, and folic acid binding mediates the uptake of antifolate drugs like methotrexate, affecting therapy efficacy [1,3].
Can folic acid binding be targeted for drug delivery?
Yes, folate-conjugated nanoparticles exploit folic acid binding to deliver drugs or nucleic acids specifically to folate receptor-positive cells [2,4,5].
What diseases are linked to defects in folic acid binding?
Defects can cause hereditary folate malabsorption, neural tube defects, megaloblastic anemia, and may influence cancer risk [1,7].
How do CRISPR models help study folic acid binding?
CRISPR knockout, knock-in, and overexpression models allow causal testing of genes involved in folate transport and binding [1,3].
What is the role of folate-binding protein in folate uptake?
Folate-binding protein can facilitate or inhibit cellular folate uptake depending on context, serving as a regulatory mechanism.
Do milk proteins bind folic acid?
Yes, alpha- and beta-caseins in milk can bind folic acid, affecting its bioavailability from dairy products.
What are synonyms for folic acid binding?
Synonyms include folate binding, vitamin B9 binding, and vitamin M binding, as listed in QuickGO for GO:0005542.
Conclusion
Folic acid binding (GO:0005542) is a fundamental molecular function that governs folate recognition, transport, and cellular uptake, with far-reaching implications for nutrition, pharmacology, and disease. The interaction between folate and its binding proteins is exploited in clinical diagnostics, antifolate chemotherapy, and targeted drug delivery [1,3,8]. Continued research using CRISPR-based models will unravel the precise mechanisms and regulatory networks of folic acid binding, paving the way for novel therapeutic strategies [1,3].
References
- 1. Merzel RL et al.. 2017. Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin.. Nanoscale 9(7):2603-2615 PMID: 28155935
- 2. Chanphai P et al.. 2018. DNA binding efficacy with functionalized folic acid-PAMAM nanoparticles.. Chem Biol Interact 290:52-56 PMID: 29800572
- 3. Merzel RL et al.. 2017. Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein.. Bioconjug Chem 28(9):2350-2360 PMID: 28731321
- 4. Chanphai P et al.. 2018. Binding efficacy of tRNA with folic acid-PAMAM nanoparticles.. Int J Biol Macromol 114:851-854 PMID: 29621502
- 5. Chanphai P et al.. 2018. DNA binding to folic acid-chitosan nanoconjugates.. J Biomol Struct Dyn 36(10):2746-2751 PMID: 28832251
- 6. Bourassa P et al.. 2012. Locating the binding sites of folic acid with milk α- and β-caseins.. J Phys Chem B 116(1):513-9 PMID: 22103859
- 7. Unknown. 1975. The inhibition of cellular uptake of folate by folic acid-binding protein.. Nutr Rev 33(6):183-4 PMID: 1095970
- 8. Rothenberg SP. 1973. Application of competitive ligand binding for the radioassay of vitamin B12 and folic acid.. Metabolism 22(8):1075-82 PMID: 4581034
